Addressing HPV Vaccine Hesitancy by Co-Designing a Digital Health Intervention (HPV-END-IT)
tiistai 2. kesäkuuta 2026 päivittänyt: Sibylle Herzig van Wees, Karolinska Institutet
HPV-Kompassen: a Mixed-Methods Single-Arm Cluster Feasibility Study of a Co-Designed Web-Based Intervention To Strengthen HPV Vaccine Confidence and Uptake in Stockholm, Sweden
This study looks at a digital platform that supports HPV vaccination in schools. The goal is to see if it is useful, easy to use, and practical in real school settings, especially in areas where fewer people get vaccinated.
Researchers will give Year 5 pupils (aged 11-12) and their parents or caregivers access to the platform. It provides clear, trusted information about the HPV vaccine for young people, parents, and school nurses. The aim is to make the vaccine easier to understand and to help answer any questions or concerns.
After using the platform, participants will be asked to share their thoughts.
Tutkimuksen yleiskatsaus
Tila
Ei vielä rekrytointia
Interventio / Hoito
Opintotyyppi
Interventio
Ilmoittautuminen (Arvioitu)
100
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskeluyhteys
- Nimi: Helena Avermark
- Puhelinnumero: +4670-890 25 04
- Sähköposti: helena.avermark@ki.se
Tutki yhteystietojen varmuuskopiointi
- Nimi: Asha Mohamed Ibrahim
- Sähköposti: asha.mohamed.ibrahim@ki.se
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Lapsi
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Joo
Kuvaus
We will aim to recruit 6-8 compulsory schools in Stockholm County to serve as clusters.
All Year 5 pupils and their caregivers in the study schools are invited.
Inclusion Criteria:
- The school provides education to pupils in school year 5 and is scheduled to be open throughout the pilot trial period
- The school is located in an area with HPV vaccine uptake <85.2% (the Stockholm regional average)
- The head principal and school nurse both consent to participate
- The school has the capacity to implement the intervention
Exclusion Criteria:
- Failure to meet the inclusion criteria
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Muut
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Intervention arm
Participants in the intervention arm receive access to the co-designed, digital platform HPV-Kompassen (eng: The HPV Compass).
|
HPV-Kompassen is a co-designed, web-based platform that provides tailored and synthesised information with the aim of strengthening confidence in and uptake of the HPV vaccine.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Feasibility of implementation: Acceptability, appropriateness and feasibility of implementation
Aikaikkuna: Shortly after the intervention period (i.e., 'end of treatment') at 7 months.
|
Measured using Weiner et al.'s implementation outcomes questionnaire (administered to school nurses in participating schools). The questionnaire consists of 12 statements, with four items each assessing the Acceptability of Intervention Measure (AIM), the Intervention Appropriateness Measure (IAM), and the Feasibility of Intervention Measure (FIM). Respondents rate their level of agreement with each statement using a five-point Likert scale, ranging from "completely disagree" to "completely agree." Responses are coded numerically from 1 to 5, with higher scores indicating stronger agreement. The 12 scores are summed to produce a total scale score ranging from 12 to 60, with higher scores reflecting more positive perceptions of the platform across the three implementation domains. |
Shortly after the intervention period (i.e., 'end of treatment') at 7 months.
|
|
Feasibility of implementation: Acceptability, appropriateness and feasibility of implementation
Aikaikkuna: Shortly after the intervention period (i.e., 'end of treatment') at 7 months.
|
Qualitative data will be collected through semi-structured interviews with school nurses in participating schools.
An interview guide developed guided by the Consolidated Framework for Implementation Research (CFIR) will be used to ensure consistency while allowing flexibility to explore individual experiences in depth.
The guide includes open-ended questions designed to capture perceptions (see outcome measure 5) and questions related to implementation, e.g., 'How did you experience implementing HPV-Kompassen alongside the regular school health services program?' and 'How well did HPV-Kompassen fit with how schools provide information about HPV vaccination?'.
|
Shortly after the intervention period (i.e., 'end of treatment') at 7 months.
|
|
Acceptability of intervention: Intervention delivery strategy
Aikaikkuna: Throughout the intervention period (i.e., months 0-7).
|
Defined as proportion of adolescents and caregivers that access platform at least once, measured through platform usage metrics.
|
Throughout the intervention period (i.e., months 0-7).
|
|
Acceptability of intervention: Usability of intervention
Aikaikkuna: Immediately after the intervention period (i.e., 'end of treatment') at 7 months.
|
Usability is measured quantitatively using the Swedish version of the System Usability Scale (SUS).
The SUS consists of 10 items assessing perceived usability across key dimensions such as complexity, ease of use, and confidence in using the system.
Participants (school nurses, adolescents and caregivers) indicate their agreement with each item on a five-point Likert scale ranging from "strongly disagree" to "strongly agree."
Responses are scored according to standard SUS procedures, resulting in a total score ranging from 0 to 100, with higher scores indicating better perceived usability.
|
Immediately after the intervention period (i.e., 'end of treatment') at 7 months.
|
|
Acceptability of intervention: Perceptions of intervention
Aikaikkuna: Shortly after the intervention period (i.e., 'end of treatment') at 7 months.
|
Qualitative data will be collected through semi-structured interviews with participants (school nurses, adolescents and caregivers), focusing on their perceptions of the intervention.
An interview guide is used to ensure coverage of key domains while allowing flexibility to explore individual experiences in depth.
The guide includes open-ended questions assessing implementation (see outcome measure 2) and perceptions of the intervention, such as "Can you briefly describe your experience of using HPV-Kompassen?" and "Did the information seem credible to you?".
|
Shortly after the intervention period (i.e., 'end of treatment') at 7 months.
|
|
Acceptability of intervention: Intervention engagement
Aikaikkuna: Throughout the intervention period (i.e., months 0-7).
|
Defined as proportion of adolescents and caregivers that actively engage with the platform least once (e.g., visit different modules), measured through platform usage metrics.
|
Throughout the intervention period (i.e., months 0-7).
|
|
Acceptability of intervention: Intervention engagement
Aikaikkuna: End of intervention period (i.e., 'end of treatment') at 7 months.
|
Qualitative data collection using semi-structured interviews.
These interviews aim to understand how, why, and to what extent participants engaged with the platform in practice.
Participants (school nurses, adolescents and caregivers) are asked open-ended questions such as "Why did you choose to use the platform?"
and "Why did you not use the platform, or use it less than expected?"
Additional questions explore when and how the platform was accessed, which features were used, and what factors influenced engagement (e.g., time constraints, relevance of content, or integration with existing workflows).
|
End of intervention period (i.e., 'end of treatment') at 7 months.
|
|
Feasibility of trial protocol: Feasibility of recruitment
Aikaikkuna: From start of school enrollment (i.e., pre-intervention) and throughout the intervention period (i.e., months 0-7).
|
Measured through study notes, assessing two indicators: proportion of schools that consent to participate and proportion of participants that consent to participate in interviews.
|
From start of school enrollment (i.e., pre-intervention) and throughout the intervention period (i.e., months 0-7).
|
|
Feasibility of trial protocol: Participant retention
Aikaikkuna: From school enrollment (i.e., 'baseline') and throughout the intervention period (i.e., months 0-7).
|
Measured using study records and platform metrics, assessing two indicators: Proportion of schools retained until study end and proportion of participants using platform who complete the end line survey.
|
From school enrollment (i.e., 'baseline') and throughout the intervention period (i.e., months 0-7).
|
|
Feasibility of trial protocol: Feasibility of data collection methods
Aikaikkuna: Shortly after the intervention period (i.e., 'end of treatment') at 7 months.
|
Measured using study records and survey data, assessing the completeness of data.
|
Shortly after the intervention period (i.e., 'end of treatment') at 7 months.
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Tutkijat
- Päätutkija: Sibylle Herzig van Wees, Associate Professor, Karolinska Institutet
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Lauantai 1. elokuuta 2026
Ensisijainen valmistuminen (Arvioitu)
Tiistai 1. kesäkuuta 2027
Opintojen valmistuminen (Arvioitu)
Tiistai 1. kesäkuuta 2027
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Keskiviikko 27. toukokuuta 2026
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Tiistai 2. kesäkuuta 2026
Ensimmäinen Lähetetty (Todellinen)
Maanantai 8. kesäkuuta 2026
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Maanantai 8. kesäkuuta 2026
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Tiistai 2. kesäkuuta 2026
Viimeksi vahvistettu
Perjantai 1. toukokuuta 2026
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muut tutkimustunnusnumerot
- 2023-00331
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
EI
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Ei
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Ei
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .